echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Index Interpretation Test Index Clinical Interpretation (20) Platelet Test (1)

    Index Interpretation Test Index Clinical Interpretation (20) Platelet Test (1)

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Platelet adhesion test

    Platelet adhesion test

    (Platelet adhesiveness test, PAdT)

    (Platelet adhesiveness test, PAdT)

    Normal value

    Normal value

    Rotation method: 0.


    Glass bead method: 0.


    Influencing factors

    Influencing factors

    1.


    2.


    3.


    4.


    Clinical interpretation

    Clinical interpretation

    1.


    Seen in hypercoagulable state or thrombotic diseases, such as myocardial infarction, venous or aortic embolism, hyperlipoproteinemia, atherosclerosis, hypertension, diabetes, certain cancers after surgery and oral contraceptives


    2.


    Seen in platelet weakness, von Willebrand disease (vWD), storage pool disease, mild platelet disease, collagen ineffective platelet disease, Hermansky-Pudiak syndrome, giant platelet syndrome, May-Hegglin abnormality, after taking aspirin and other drugs, Liver disease, uremia, leukemia, thrombocytosis, glycogen storage disease (type I), congenital fibrinogen deficiency, and after eating fish oil


    Platelet aggregation test

    Platelet aggregation test

    (Platelet aggregation test, PAgT)

    (Platelet aggregation test, PAgT)

    Normal value

    Normal value

    1.


    2.


    Influencing factors

    Influencing factors

    1.


    2.


    3.


    4.


    5.
    Because it is a turbidimetric method, it avoids the interference of hemolysis, red blood cell mixing, and lipid substances such as milk and soy milk
    .

    6.
    Aspirin, dipyridamole, heparin, and dicoumarin drugs should not be used within 1 week before the test
    .

    7.
    The platelet aggregation test is greatly affected by the environment and reagents of the day.
    It is best to use normal human platelets as a control each time
    .

    8.
    The effect of platelet aggregation increases as the concentration of sodium citrate in the plasma decreases.
    Therefore, more anticoagulants should be added to patients with anemia than normal ones
    .

    9.
    The specimens after blood collection should be placed at room temperature of 15~25℃.
    Low temperature will increase the platelet activation and aggregation ability
    .

    Clinical interpretation

    Clinical interpretation

    1.
    Increased platelet aggregation: suggesting increased platelet activity, seen in post-surgery, diabetes, acute myocardial infarction, venous thrombosis, bruising congenital heart disease, pneumonia, hyper β lipoproteinemia, rejection of bone transplantation, artificial heart valve transplantation and multiple sclerosis
    .
    Oral contraceptives, high-fat diets, and smoking can also cause increased platelet aggregation
    .

    2.
    Decreased platelet aggregation: suggesting platelet dysfunction, seen in platelet weakness (Glanzmann disease), primary and secondary platelet disease Bernard-Soulier syndrome, abnormal release response (reservoir disease), von Willebrand disease , May-Hegglin abnormality, Swisscheese disease, congenital hypofibrinogenemia, persistent and severe liver disease, Wilson disease, kidney disease (uremia), vitamin B12 deficiency, bacterial endocarditis, antiplatelet antibodyemia and Postoperative hypofibrinogenemia and so on
    .

    3.
    The use of certain drugs, such as aspirin, dextran, phenylbutazone, etc.
    , can reduce aggregation.
    Therefore, the relevant drugs should be stopped before this test
    .

    Platelet thrombin sensitive protein

    Platelet thrombin sensitive protein

    (Platelet thrompospondin, TSP)

    (Platelet thrompospondin, TSP)

    Normal value

    Normal value

    1.
    Human plasma content

    Enzyme-linked immunosorbent assay (ELISA method): (105.
    0±31.
    6) μg/L platelets
    .

    2.
    Serum content

    Enzyme-linked immunosorbent assay (ELISA method): (25.
    3 ± 5.
    70) μg/L platelets
    .

    3.
    Whole blood content

    Enzyme-linked immunosorbent test (ELISA method): (18.
    0 ± 3.
    39) μg/L platelets
    .

    4.
    Platelet content

    Enzyme-linked immunosorbent assay (ELISA method): (89.
    1±28.
    26) μg/L platelets
    .

    Influencing factors

    Influencing factors

    1.
    In the TSP test, attention should be paid to the in vitro activation of platelets, and the smooth blood collection should be emphasized
    .

    2.
    Siliconization of glassware or the use of plastic products is necessary
    .
    Because glass can activate the coagulation reaction
    .

    3.
    TSP can be released into the blood in large quantities due to the growth and metastasis of tumor cells, especially in adenocarcinoma
    .

    Clinical interpretation

    Clinical interpretation

    Increased TSP is seen in prethrombotic states and thrombotic diseases, such as acute myocardial infarction, unstable angina, diabetes with microangiopathy, hyperlipidemia, hypertension, cerebrovascular disease, deep vein thrombosis, DIC, nephrotic syndrome, pulmonary embolism, pregnancy and post-pregnancy toxemia
    .
    TSP is not as specific as β-TG and PF4
    .

    Platelet (plasma) surface α-granule membrane protein 140 detection

    Platelet (plasma) surface α-granule membrane protein 140 detection

    [Platelet(plasma)α-gran-ule membrane protein 140, GMP-140]

    [Platelet(plasma)α-gran-ule membrane protein 140, GMP-140]

    Normal value

    Normal value

    Radioimmunoassay (RIA method): (780±490) number of molecules/platelets
    .

    Radioimmunoassay (RIA method): (1.
    61±0.
    72) x1010 molecules/L plasma
    .

    Influencing factors

    Influencing factors

    1.
    It is best to use siliconized or plastic syringes, glass test tubes, etc.
    , which need to be coated with silicon, because glass can activate the coagulation reaction
    .

    2.
    The ideal anticoagulant should be sodium citrate
    .

    3.
    The tourniquet should not be tied too tightly, preferably no more than 5 minutes, and it should be emphasized that the blood collection is smooth to prevent activation of the coagulation reaction
    .

    Clinical interpretation

    Clinical interpretation

    1.
    Reduce

    Mainly seen in platelet weakness (deficiency of GPⅡb, GPⅡa), giant platelet syndrome (deficiency of GPⅠb, GPⅨ), primary thrombocytopenic purpura (platelet protein autoantibodies may be present in the body)
    .

    2.
    Increase

    In the prethrombotic state and thrombotic diseases, elevated GMP-140 can be used as a specific molecular marker of platelet activation
    .

    Plasma fibronectin

    Plasma fibronectin

    (Plasma fibronectin, Fn)

    (Plasma fibronectin, Fn)

    Normal value

    Normal value

    Enzyme-linked immunosorbent test (ELISA method): 277~513mg/L.

    Influencing factors

    Influencing factors

    1.
    It is best to use siliconized or plastic syringes, glass test tubes, etc.
    , which need to be coated with silicon, because glass can activate the coagulation reaction
    .

    2.
    Pay attention to the preservation of specimens, preferably fresh specimens
    .

    3.
    If it is not a fresh specimen, whether it is taken from -80°C or -20°C, it must be in 37°C clean water to avoid affecting the measurement results
    .

    4.
    In order to prevent heparin and EDTA anticoagulant from forming cryoprecipitate or becoming unstable with Fn, it is better to use sodium citrate anticoagulant for blood samples
    .

    Clinical interpretation

    Clinical interpretation

    1.
    Increased plasma Fn concentration

    It is found in acute hepatitis and chronic hepatitis, fatty liver, liver cirrhosis, obstructive jaundice, cerebrovascular disease, late pregnancy, pregnancy-induced hypertension, pancreatic cancer, lung cancer, cancerous ascites and adenocarcinoma with widespread metastasis
    .

    2.
    Decreased plasma Fn concentration

    Found in acute leukemia, DIC, acute severe hepatitis, burns, trauma, shock, bacterial or viral infections, acute respiratory distress syndrome, diabetes complicated by ketoacidosis, uremia, acute circulatory failure, menopausal women and some chemotherapy Poorly tolerated patients
    .

     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.